Innovative strategies lead to mixed benefits for rare cancers
Positive findings are presented for advanced Merkel-cell carcinoma plus phaeochromocytoma and paragangliomas, while negative findings are equally important to guide future research
Novel strategies to overcome resistance to immune checkpoint inhibitors show promise in early studies
Blocking GDF-15, an mRNA-based therapy and targeting VISTA have a strong mechanistic rationale, resulting in clinical benefit in heavily pre-treated patients
Survival improvements observed with first-line antibody–drug conjugates in triple-negative breast cancer
TROP2-targeted ADCs, sacituzumab govitecan and datopotamab deruxtecan, meet their primary endpoints in phase III trials
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Sustained benefits of neoadjuvant immunotherapy demonstrated in resectable melanoma
Longer follow-up from two studies supports neoadjuvant over adjuvant immune checkpoint inhibition in patients with resectable melanoma and clinically or radiologically detectable metastasis, plus useful insights gained from biomarker analyses will help refine treatment strategies
ctDNA shapes anti-EGFR rechallenge strategies in metastatic colorectal cancer
Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge
What is next for radiopharmaceuticals in NETs?
While early-phase findings confirm the efficacy and mild toxicity of radiopharmaceuticals, patient selection and logistical issues limit their integration into broad clinical practice
A novel off-the-shelf cancer vaccine shows some potential in PD-L1-negative patients with advanced melanoma
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
Zanzalintinib plus atezolizumab shows activity in metastatic colorectal cancer with microsatellite stable disease
Primary phase III overall survival analysis suggests that the combination therapy may be a potential new option for previously treated patients with or without liver metastases